Alfuzosin Hydrochloride

WEDNESDAY, June 20, 2024 -- Prostate medications might help reduce the risk of a specific type of dementia , a new study suggests. People were less likely to develop Lewy body dementia when taking drugs designed to treat urinary symptoms caused by an enlarged prostate, researchers reported June 19 in the journal Neurology . “These results are exciting, because right now there are no drugs to prevent or treat dementia with Lewy bodies, which is the second most common neurodegenerative type of dementia after Alzheimer’s disease,” said researcher Jacob Simmering , an assistant professor of internal medicine with the University of Iowa. “If we can determine that an existing drug can offer protection against this debilitating disease, that has the potential to greatly reduce its effects,” Simmering added in a journal news release. Lewy body dementia affects more than 1 million people in the United States, according to the National Institute on Aging (NIA). It’s caused by the protein alpha-synuclein, which forms abnormal deposits called Lewy bodies that affect chemicals in the brain. This form of dementia can cause thinking and memory issues, movement problems and even visual hallucinations, the NIA says. More than 80% of people with Lewy body dementia see things that aren’t really there. For this study, researchers focused on the drugs terazosin , doxazosin and alfuzosin , which help men urinate more easily despite an enlarged prostate. These meds help relax muscles in the prostate and bladder. However, the three drugs also activate an enzyme important for energy production in brain cells, and previous studies have shown a link between these drugs and Parkinson’s disease, researchers said. Lewy body dementia is similar to Parkinson’s, so researchers decided to see if the drugs might help these patients as well. Researchers analyzed data on more than 126,000 men taking one of the three drugs, and compared them against more than 517,000 men taking two other types of prostate medication that don’t activate that enzyme. Results show that men taking one of the three drugs were around 40% less likely to develop Lewy body dementia than those taking the two other meds. “More research is needed to follow people over time and determine whether there is a cause-and-effect relationship here, but it is promising to think that these drugs could have a protective effect on this disease that will likely affect a larger number of people as the population ages,” Simmering said. Researchers warned that since only men were included in the study, the results might not apply to women. Lewy body dementia appears to affect slightly more men than women, the NIA notes. In addition, Lewy body dementia can be tough to diagnose, so it’s possible the researchers didn’t catch everyone who’d developed the brain disease. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Pictured: Concept art showing an elderly woman overlaid with an illustration of a brain/iStock, boonstudio Drugs commonly used for the treatment of enlarged prostate may also help lower the risk of dementia with Lewy bodies, according to a new observational study from the University of Iowa Health Care. Drawing from Merative MarketScan, one of the largest proprietary U.S. healthcare claims databases, University of Iowa researchers identified more than 643,000 men who were starting treatment for benign prostatic hyperplasia with one of six common therapies. Three of these drugs fell under the class of α-1 adrenergic receptor antagonists, better known as α-blockers, which work by inhibiting the contraction of smooth muscles. The researchers focused on terazosin, which is sold by Abbott under the brand name Hytrin, doxazosin, which is marketed by Pfizer as Cardura, and alfuzosin, which is branded as Uroxatral by Sanofi. Alpha-blocker drugs are known to have a unique side effect: they activate a key enzyme involved in the production of ATP, which is the molecular form of cellular energy. In the brain, these drugs can help boost the production of energy and fight neurodegeneration, the University of Iowa scientists hypothesized. As active comparators, the researchers also followed men in Merative MarketScan who were being treated with tamsulosin or with the 5α-reductase inhibitors (5ARI) finasteride and dutasteride, all of which are not known to affect energy production in the brain. The men included in the study had no history of dementia with Lewy bodies (DLB). Participants were then followed until they exited the database or until they developed DLB. After an average follow-up of around three years, the study found that men who were initiated on the three alpha-blocker drugs were 40% less likely to develop DLB than comparators who were on tamsulosin. Compared with men whose enlarged prostates were being treated with 5ARI agents, the risk of DLBA was 27% lower in those taking alpha-blocker drugs. Both effects were statistically significant. By contrast, DLB had a statistically similar likelihood of developing in men being managed with tamsulosin and 5ARIs. These results were robust to several sensitivity analyses, according to researchers. The University of Iowa scientists published their findings Wednesday in Neurology, the medical journal of the American Academy of Neurology. “If terazosin and these similar medications can help slow this progression—if not outright preventing the disease—this would be important to preserving cognitive function and quality of life in people with DLB,” Jacob Simmering, assistant professor of internal medicine at the University of Iowa and lead study author, said in a statement. However, the researchers caution that the study is simply observational in design and only shows that there is a statistical correlation between the use of alpha-blocker drugs and the reduced risk of DLB. It does not establish causation nor does it show any directionality of association, they said. Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.